IRVINE, Calif., May 21, 2017 -- Pain Management Center of Irvine recently released information on the superiority of SurForce® compared to prolotherapy or PRP. Unlike the alternatives, which take hours per appointment, SurForce® only requires 15 minutes per session. SurForce® is also painless, while the other two options can be painful. The SurForce® treatments also promote healing rather than only managing pain.
Prolotherapy is an older treatment method that involves injecting dextrose into painful tissues to intentionally cause an inflammatory response. The underlying belief is that it will cause the body to speed healing in the inflamed area as well as the injured part. In practice, however, it is used to manage pain instead of to regenerate tissue. Unfortunately, the inflammation it brings on actually causes pain for the duration of the treatments.
Platelet Rich Plasma (PRP) is a stem cell therapy made up of blood, bone marrow, and fat (adipose) tissue. Getting these ingredients involves sucking bone marrow and fat out of the patient's body, and this is said to be a very painful process. It is even worse for older patients since they have fewer viable stem cells and need to donate more tissue to make up for this.
"It is clear that these older methods each have significant shortcomings. This is why we decided to implement the SurForce® system instead. SurForce® combines amniotic membrane tissue, biological scaffolding, and hyaluronic acid to provide a strong healing boost to painful areas via the addition of stem cells. This not only relieves pain, but allows the body to heal faster. Even better, this treatment is delivered by a painless injection," explained Dr. Rick Letts of Pain Management Center of Irvine.
Many people have questions when they learn that amniotic membrane is part of the SurForce® treatment. Specifically, they want to know where it comes from. There is no need for concern over this aspect of SurForce®. The FDA regulated amniotic membrane is voluntarily donated by women who have had cesarean deliveries.
Like many other healing treatments, SurForce® takes several weeks to fully implant in a patient, which is when the most noticeable improvement to their condition can be observed. Therefore, patients are advised to stick to light activity for the first few weeks. This ensures that everything will heal properly and prevent further injury during the course of treatment.
About Pain Management Center of Irvine
The Center offers a wide variety of pain management treatments, ranging from advanced stem cell therapy all the way to traditional healing methods like acupuncture and cupping. It serves the area of Irvine, CA.
To learn more about SurForce®, visit the Pain Management Center of Irvine’s website at http://chirocenterofirvine.com/.
Pain Management Center of Irvine 4902 Irvine Center Dr. #201 Irvine, CA 92604 (949) 857-4712


Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals
Google Halts UK YouTube TV Measurement Service After Legal Action
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI
ASML’s EUV Monopoly Powers the Global AI Chip Boom
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 



